drugset / Trial / NCT03235232

BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension

NCT03235232

Phase 3 Completed 406 enrolled EMS
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.

Timeline

Start
2021-02-01
Primary completion
2023-07-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BREMEN eye drops Unknown Topical
Comparator Combigan Unknown Topical